Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486). 1971

M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett

UI MeSH Term Description Entries
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide

Related Publications

M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
May 1975, European journal of pharmacology,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
January 1975, Folia psychiatrica et neurologica japonica,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
January 1973, Confinia neurologica,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
March 1976, Ceskoslovenska neurologie a neurochirurgie,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
January 1978, Biochemical Society transactions,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
May 1975, European journal of pharmacology,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
January 1974, New York state journal of medicine,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
August 1974, Australian and New Zealand journal of medicine,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
March 1976, Biulleten' eksperimental'noi biologii i meditsiny,
M D Yahr, and R C Duvoisin, and M R Mendoza, and M J Schear, and R E Barrett
May 1969, Nordisk medicin,
Copied contents to your clipboard!